{
    "clinical_study": {
        "@rank": "107563", 
        "arm_group": [
            {
                "arm_group_label": "Vitamin D + fish oil placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "Vitamin D3 (cholecalciferol), 2000 IU per day Fish oil placebo"
            }, 
            {
                "arm_group_label": "Vitamin D placebo + fish oil", 
                "arm_group_type": "Active Comparator", 
                "description": "Vitamin D placebo Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
            }, 
            {
                "arm_group_label": "Vitamin D placebo + fish oil placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vitamin D placebo fish oil placebo"
            }, 
            {
                "arm_group_label": "Vitamin D + fish oil", 
                "arm_group_type": "Active Comparator", 
                "description": "Vitamin D (cholecalciferol), 2000 IU per day Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
            }
        ], 
        "brief_summary": {
            "textblock": "The VITamin D and OmegA-3 Trial (VITAL; NCT 01169259) is a randomized clinical trial in\n      25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin\n      D3 (2000 IU) or omega-3 fatty acids (Omacor fish oil, 1 gram) reduces the risk of developing\n      cancer, heart disease, and stroke in people who do not have a prior history of these\n      illnesses. This ancillary study is being conducted among participants in VITAL and will\n      examine whether omega-3 fatty acids or vitamin D3, compared to placebo, reduce the incidence\n      and/or progression of dry eye disease."
        }, 
        "brief_title": "Dry Eye Disease in the Vitamin D and Omega-3 Trial (VITAL)", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Dry Eye Disease", 
        "condition_browse": {
            "mesh_term": [
                "Keratoconjunctivitis Sicca", 
                "Dry Eye Syndromes", 
                "Eye Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "This ancillary study to VITAL will examine the efficacy of omega-3 fatty acids and vitamin\n      D3 in prevention of dry eye disease. The primary aims are to test whether omega-3 fatty acid\n      supplementation (1) reduces the incidence of dry eye disease, and (2) improves the natural\n      history of dry eye disease by relieving symptoms and other impacts on quality of life.\n      Secondary aims are to estimate the incidence of dry eye disease in the US, prospectively\n      examine the natural history of dry disease, explore factors that could modify or influence\n      the impact of omega-3 fatty acid supplementation, evaluate the interrelationship of dry eye\n      disease and depression, and test for possible independent or joint effects of vitamin D3\n      supplementation in the incidence and natural history of dry eye disease."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All participants in VITAL (NCT 01169259) are eligible to participate in this\n             ancillary study.\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "25875", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01880463", 
            "org_study_id": "2012P001332", 
            "secondary_id": "R01EY022663"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Vitamin D placebo + fish oil", 
                    "Vitamin D + fish oil"
                ], 
                "intervention_name": "Omega-3 fatty acids (fish oil)", 
                "intervention_type": "Drug", 
                "other_name": "Omacor"
            }, 
            {
                "arm_group_label": [
                    "Vitamin D + fish oil placebo", 
                    "Vitamin D + fish oil"
                ], 
                "intervention_name": "Vitamin D3", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "cholecalciferol"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Dry eye disease", 
            "incidence", 
            "progression"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "link": {
            "description": "Welcome to the VITAL Study website", 
            "url": "http://vitalstudy.org"
        }, 
        "number_of_arms": "4", 
        "official_title": "Dry Eye Disease in the Vitamin D and Omega-3 Trial (VITAL)", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Report of a diagnosis of dry eye disease confirmed by medical record review.", 
            "measure": "Dry Eye Disease", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01880463"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Brigham and Women's Hospital", 
            "investigator_full_name": "Debra Schaumberg", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Brigham and Women's Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "National Eye Institute (NEI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Brigham and Women's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}